Online citations, reference lists, and bibliographies.
← Back to Search

A Phase II Study Of Intermittent Sunitinib Malate As Second-Line Therapy In Progressive Malignant Pleural Mesothelioma

A. Nowak, M. Millward, J. Creaney, R. Francis, I. Dick, A. Hasani, A. A. van der Schaaf, A. Segal, A. Musk, M. Byrne
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Introduction: There is no accepted second-line therapy for patients with advanced malignant pleural mesothelioma (MPM), whose disease has progressed after first-line chemotherapy. The multitargeted tyrosine kinase inhibitor sunitinib malate targets several pathways overexpressed in mesothelioma. This phase II study assessed objective response to sunitinib and correlative biomarkers in patients with progressive pretreated MPM. Methods: Eligible patients had confirmed MPM, radiological progression after chemotherapy, Eastern Cooperative Oncology Group performance status 0 to 1, and measurable disease. Patients received oral sunitinib 50 mg daily for 28 of every 42 days. The primary endpoint was objective radiological response. Patients without prior pleurodesis had fluorodeoxyglucose positron emission tomographic response assessed by total glycolytic volume criteria. Correlative biomarkers included serum mesothelin, vascular endothelial growth factor (VEGF)-A, VEGF-C, interleukin-8, sVEGFR-2, sVEGFR-3, and s-kit. Results: Fifty-three patients received sunitinib between July 2006 and December 2009; 51 were assessable for response. Patients received a median of two cycles (range, 1–12); 40% required dose reduction. Fatigue was the most prominent toxicity. Six patients (12%) had a confirmed radiological partial response, 34 (65%) had stable disease, and 11 (22%) had progressive disease as best response. Six of 20 patients had a decrease in fluorodeoxyglucose positron emission tomographic total glycolytic volume of 15% or more. Median overall survival was 6.1 months, and median time to progression was 3.5 months. Correlative biomarkers did not predict treatment response. Conclusions: Sunitinib has activity in a subset of patients with pretreated MPM. Consideration should be given to different treatment schedules and examination of other biomarkers for further study of sunitinib in MPM.
This paper references
10.1002/(SICI)1096-9896(199602)178:2<151::AID-PATH425>3.0.CO;2-E
EXPRESSION OF PLATELET‐DERIVED GROWTH FACTOR (PDGF) AND PDGF RECEPTORS IN HUMAN MALIGNANT MESOTHELIOMA IN VITRO AND IN VIVO
A. Langerak (1996)
10.1200/JCO.2008.26.15_SUPPL.14614
A phase II trial of gefitinib in patients with malignant pleural mesothelioma (MPM)
C. Lee (2008)
10.1200/JCO.2004.22.90140.7021
A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC.
J. Van Meerbeeck (2004)
10.1200/JCO.2007.25.18_SUPPL.7526
Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)
T. Karrison (2007)
10.1200/JCO.2007.25.18_SUPPL.7707
Sorafenib in malignant mesothelioma (MM): A phase II trial of the Cancer and Leukemia Group B (CALGB 30307)
P. Jänne (2007)
10.1097/JTO.0b013e3182333df5
Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
S. Laurie (2011)
10.1038/ki.2009.552
Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib.
C. Porta (2010)
10.1378/CHEST.07-0013
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
J. Creaney (2007)
10.1158/1078-0432.CCR-09-1980
E7080, a Multi–Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles
K. Ikuta (2009)
10.1165/AJRCMB.24.6.4334
Paradoxical effects of platelet-derived growth factor-A overexpression in malignant mesothelioma. Antiproliferative effects in vitro and tumorigenic stimulation in vivo.
L. Metheny-Barlow (2001)
10.1073/pnas.0708148104
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
J. Ebos (2007)
10.1038/sj.bjc.6605346
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
S. Novello (2009)
10.1038/sj.bjc.6605303
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
H. Kalantari (2009)
2nd, et al.; Cancer and Leukemia Group B (CALGB 30101). Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia
R Govindan (2005)
10.1158/1078-0432.CCR-10-1929
Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden
J. Creaney (2010)
10.1378/CHEST.125.6.2356
Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis.
B. H. Kwek (2004)
10.1159/000029460
Co-Expression of Vascular Endothelial Growth Factor and Its Receptor flt-1 in Malignant Pleural Mesothelioma
J. Koenig (2000)
10.1097/01.MP.0000083647.69123.5C
c-Kit Is Not Expressed in Malignant Mesothelioma
A. Horvai (2003)
10.1007/s00280-006-0243-4
Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma
C. Porta (2006)
10.1002/ijc.10996
Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF‐C autocrine loops
R. Masood (2003)
10.1200/JCO.2008.20.9908
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
A. Zhu (2009)
10.1016/j.ejca.2009.02.011
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
S. George (2009)
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced nonsmall cell lung cancer
S Novello (2009)
10.1007/s004280050388
Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma
J. König (1999)
10.1158/1078-0432.CCR-06-0919
Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor
A. Norden-Zfoni (2007)
Expression of c-sis (PDGF B-chain) and PDGF A-chain genes in ten human malignant mesothelioma cell lines derived from primary and metastatic tumors.
M. Versnel (1988)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1200/JCO.2008.16.1612
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
B. Schneider (2008)
10.1200/JCO.2006.09.7634
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
10.2967/jnumed.107.042333
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
R. Francis (2007)
10.2967/jnumed.108.057307
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
R. Wahl (2009)
10.1002/cncr.23617
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
D. Jackman (2008)
10.1158/0008-5472.CAN-09-3965
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.
Dan Huang (2010)
FDG-PET imaging demonstrates kinase target inhibition by sunitinib malate (SU11248) in GIST patients resistant to or intolerant of imatinib mesylate
AD Van den Abbele (2005)
10.1074/JBC.M406696200
Induction of Stem Cell Factor/c-Kit/Slug Signal Transduction in Multidrug-resistant Malignant Mesothelioma Cells*
A. Catalano (2004)
10.1158/1078-0432.CCR-07-0501
The Therapeutic Efficacy of Anti–Vascular Endothelial Growth Factor Antibody, Bevacizumab, and Pemetrexed against Orthotopically Implanted Human Pleural Mesothelioma Cells in Severe Combined Immunodeficient Mice
Q. Li (2007)
10.1378/CHEST.128.5.3382
Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma.
F. Demirag (2005)
10.1158/1078-0432.CCR-04-1940
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)
10.1200/JCO.2006.24.18_SUPPL.7081
Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107).
T. Jahan (2006)
10.1016/j.ygyno.2009.11.011
The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer.
K. Steffensen (2010)
10.1093/ANNONC/MDM408
A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.
J. Christensen (2007)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1186/1479-5876-5-32
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
S. Deprimo (2007)
10.1016/j.ejca.2009.02.022
Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines.
J. Nutt (2009)
10.1200/JCO.2008.20.5476
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
B. Escudier (2009)
10.1200/jco.2009.27.15_suppl.7578
A multicenter phase II study of pemetrexed (P), cisplatin (C), and bevacizumab (B) in patients (pts) with advanced malignant mesothelioma (MM).
J. Dowell (2009)
10.1200/jco.2009.27.15_suppl.7511
SWOG S0509: A phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma.
L. Garland (2009)
10.1097/JTO.0b013e3181d2f008
Clinical Significance of Serum Vascular Endothelial Growth Factor in Malignant Pleural Mesothelioma
A. Yasumitsu (2010)



This paper is referenced by
KAT 5 ( Tip 60 ) is a potential therapeutic target in malignant pleural mesothelioma
S. Cregan ()
Nintedanib : new treatment for malignant pleural mesothelioma
(2017)
10.1586/17476348.2015.1083426
Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review
O. Abdel-Rahman (2015)
10.1586/17476348.2015.1081066
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies
A. Bononi (2015)
10.2147/OTT.S113598
Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date
Pavel A. Levin (2017)
A new standard for malignant pleural mesothelioma
Aneel Bhangu (2016)
10.1055/s-0034-1365025
[Malignant pleural mesothelioma: new aspects of medical therapy].
S. Kurz (2014)
10.1080/14656566.2016.1176145
Advances in treatment of mesothelioma
C. Maggioni (2016)
10.2217/LMT.15.32
New directions in mesothelioma treatment
Anna K. Nowak (2015)
10.1097/JTO.0b013e31828c2b26
Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
S. Papa (2013)
10.4161/onci.26218
Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients
J. Stevenson (2013)
10.1111/1759-7714.13491
Gender differences in molecular‐guided therapy recommendations for metastatic malignant mesothelioma
H. Taghizadeh (2020)
10.2147/LCTT.S135802
A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma
M. O. Jamil (2017)
alignant pleural mesothelioma
F. Honeyball (2013)
10.1200/JCO.2016.34.15_SUPPL.8555
Genomic Landscape of Malignant Mesotheliomas.
S. Kato (2016)
10.13032/TJOP.2052-5931.100120
The Role of Surgery in Malignant Pleural Mesothelioma
Levon Toufektzian (2015)
10.1177/1753465816628800
Malignant pleural mesothelioma: an update on diagnosis and treatment options
Sanjana Kondola (2016)
10.1007/978-3-319-31215-6_22-1
Inhibition of Tumor Angiogenesis in the Treatment of Lung Cancer
Massimo Di Maio (2017)
10.1200/JCO.2013.53.0204
Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.
V. Prasad (2014)
10.1007/978-3-030-16884-1_10
Measuring Malignant Pleural Mesothelioma
A. Nowak (2019)
10.1016/j.lungcan.2013.05.006
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
A. Nowak (2013)
10.1002/ccr3.1775
Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy
F. Grosso (2018)
10.1016/j.lungcan.2014.08.017
Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials.
A. Mansfield (2014)
10.21037/tlcr.2020.01.16
Chemotherapy options versus "novel" therapies: how should we treat patients with malignant pleural mesothelioma.
M. Disselhorst (2020)
10.3390/ijms18112293
The Effect of Aquaporin 1-Inhibition on Vasculogenic Mimicry in Malignant Mesothelioma
E. Pulford (2017)
10.1016/j.jtho.2016.01.014
A Randomized Phase II Study Adding Axitinib to Pemetrexed‐Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single‐Center Trial Combining Clinical and Translational Outcomes
W. Buikhuisen (2016)
10.1053/j.seminoncol.2019.06.001
Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
A. Tsao (2019)
10.5301/tj.5000436
Systemic Approach to Malignant Pleural Mesothelioma: What News of Chemotherapy, Targeted Agents and Immunotherapy?
D. Signorelli (2016)
10.1183/2312508x.10024219
Mesothelioma: is chemotherapy alone a thing of the past?
A. Bibby (2020)
10.1007/978-3-319-53560-9_15
Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma
M. Zauderer (2017)
10.1016/j.jare.2014.11.012
Mesothelioma treatment: Are we on target? A review
B. Hiddinga (2015)
10.1016/S0140-6736(15)01311-2
A new standard for malignant pleural mesothelioma
M. Zauderer (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar